ATE446951T1 - Verwendung einer verbingung gemäss formel i zur herstellung einer pharmazeutischen zubereitung - Google Patents

Verwendung einer verbingung gemäss formel i zur herstellung einer pharmazeutischen zubereitung

Info

Publication number
ATE446951T1
ATE446951T1 AT03090177T AT03090177T ATE446951T1 AT E446951 T1 ATE446951 T1 AT E446951T1 AT 03090177 T AT03090177 T AT 03090177T AT 03090177 T AT03090177 T AT 03090177T AT E446951 T1 ATE446951 T1 AT E446951T1
Authority
AT
Austria
Prior art keywords
independently selected
optionally substituted
valence bond
optionally
hydrogen
Prior art date
Application number
AT03090177T
Other languages
English (en)
Inventor
Ricardo Biondi
Matthias Engel
Original Assignee
Biondi Ricardo Miguel
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biondi Ricardo Miguel filed Critical Biondi Ricardo Miguel
Application granted granted Critical
Publication of ATE446951T1 publication Critical patent/ATE446951T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/12—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by halogen atoms or by nitro or nitroso groups
    • C07C233/15—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by halogen atoms or by nitro or nitroso groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/64—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C233/81—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups
    • C07C233/82—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
    • C07C233/87—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom of a carbon skeleton containing six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
    • C07C323/51—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C323/52—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT03090177T 2003-06-10 2003-06-10 Verwendung einer verbingung gemäss formel i zur herstellung einer pharmazeutischen zubereitung ATE446951T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP03090177A EP1486488B1 (de) 2003-06-10 2003-06-10 Verwendung einer Verbingung gemäss Formel I zur Herstellung einer pharmazeutischen Zubereitung

Publications (1)

Publication Number Publication Date
ATE446951T1 true ATE446951T1 (de) 2009-11-15

Family

ID=33185917

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03090177T ATE446951T1 (de) 2003-06-10 2003-06-10 Verwendung einer verbingung gemäss formel i zur herstellung einer pharmazeutischen zubereitung

Country Status (5)

Country Link
US (1) US20070032474A1 (de)
EP (1) EP1486488B1 (de)
AT (1) ATE446951T1 (de)
DE (1) DE60329831D1 (de)
WO (1) WO2004111008A2 (de)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007509173A (ja) 2003-10-24 2007-04-12 シエーリング アクチエンゲゼルシャフト インドリノン誘導体類及び疾病状態、例えば癌の処理へのそれらの使用
AU2007225088B2 (en) 2006-03-13 2012-09-13 Kyorin Pharmaceutical Co., Ltd Aminoquinolones as GSK-3 inhibitors
US20070286864A1 (en) * 2006-06-09 2007-12-13 Buck Elizabeth A Combined treatment with an EGFR kinase inhibitor and an agent that sensitizes tumor cells to the effects of EGFR kinase inhibitors
WO2008019890A2 (en) * 2006-08-18 2008-02-21 Biondi Ricardo M Method of modulation of protein phosphorylation-dependent conformational transitions with low molecular weight compounds
WO2009035634A2 (en) 2007-09-11 2009-03-19 Activx Biosciences, Inc. Cyanoaminoquinolones and tetrazoloaminoquinolones as gsk-3 inhibitors
CN102344457B (zh) 2007-09-12 2015-07-22 杏林制药株式会社 作为 gsk-3 抑制剂的螺环状氨基喹诺酮
WO2009151618A2 (en) 2008-06-10 2009-12-17 Caritas St. Elizabeth's Medical Center Of Boston, Inc. Methods and compositions for treating alzheimer's disease
EP2177510A1 (de) 2008-10-17 2010-04-21 Universität des Saarlandes Allosterische Proteinkinasemodulatoren
WO2010104307A2 (ko) * 2009-03-07 2010-09-16 주식회사 메디젠텍 세포핵에서 세포질로의 ｇｓｋ３의 이동을 억제하는 화합물을 함유하는 세포핵에서 세포질로의 gsk3 이동에 의해 발생되는 질환의 치료 또는 예방용 약학적 조성물
BRPI1008974A2 (pt) 2009-03-11 2017-06-06 Kyorin Seiyaku Kk composto, composição farmacêutica, e, método para tratar, prevenir ou melhorar uma doença mediada com gsk-3
WO2013024028A1 (en) * 2011-08-12 2013-02-21 Institut National De La Sante Et De La Recherche Medicale (Inserm) Compounds and compositions for treating proteinopathies
WO2015075051A1 (en) 2013-11-19 2015-05-28 Universitaet Des Saarlandes Allosteric inhibitors of atypical protein kinases c
US20160331746A1 (en) 2015-05-12 2016-11-17 University Of South Florida Sortilin-Binding Small Molecules for Increasing Glucose Uptake
EP3325100A4 (de) 2015-07-17 2019-02-20 Memorial Sloan-Kettering Cancer Center Kombinationstherapie mit pdk1- und pi3k-inhibitoren

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000059875A2 (en) * 1999-04-05 2000-10-12 City Of Hope Novel inhibitors of formation of advanced glycation endproducts (age's)
US6037357A (en) * 1999-04-21 2000-03-14 Unitech Pharmaceuticals, Inc. N-benzoyl-α-alkylated azatyrosines as anticancer agents
TWI262185B (en) * 1999-10-01 2006-09-21 Eisai Co Ltd Carboxylic acid derivatives having anti-hyperglycemia and anti-hyperlipemia action, and pharmaceutical composition containing the derivatives
IL136458A0 (en) * 2000-05-30 2001-06-14 Peptor Ltd Protein kinase inhibitors
IL155092A0 (en) * 2000-09-29 2003-10-31 Glaxo Group Ltd Compounds useful in the treatment of inflammatory diseases
WO2002079786A2 (en) * 2001-03-30 2002-10-10 Biostratum Ab Method for identifying drugs for the treatment of type ii diabetes
EP1417303A2 (de) * 2001-08-14 2004-05-12 Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute for Biomedical Research Kinase-kristallstrukturen

Also Published As

Publication number Publication date
EP1486488B1 (de) 2009-10-28
DE60329831D1 (de) 2009-12-10
EP1486488A1 (de) 2004-12-15
US20070032474A1 (en) 2007-02-08
WO2004111008A2 (en) 2004-12-23
WO2004111008A3 (en) 2005-03-17

Similar Documents

Publication Publication Date Title
ATE446951T1 (de) Verwendung einer verbingung gemäss formel i zur herstellung einer pharmazeutischen zubereitung
EP1795536A4 (de) Phosphoramiditverbindung und verfahren zur herstellung von oligo-rna
EA200300428A1 (ru) Антагонисты метаботропных рецепторов глутамата
ATE313535T1 (de) Pyrazinyl-piperazin-verbindungen, ihre anwendung und herstellung
CY1109222T1 (el) Παραγωγο συγχωνευμενης κινολινης και χρηση του
DE68906183D1 (de) 2'-desoxy-5-fluoruridinderivate.
ATE338754T1 (de) Heterocyclische verbindungen, ihre herstellung und verwendung
DK1814846T3 (da) 11beta-HSD1-inhibitorer
NL300194I1 (nl) Nieuwe tricyclische verbindingen.
MXPA04009784A (es) Tiazolidin-4-carbonitrilos y analogos y su uso como inhibidores de dipeptidil-peptidas.
CY1112835T1 (el) Ενωσεις κιναζολινης
EE9800149A (et) Meetod taksaanide külgahela prekursorite valmistamiseks, sellel meetodil saadud ühendid, ning taksaanide valmistamismeetod ja nende derivaadid
EA199800794A1 (ru) Новые производные арилглициламида, способ их получения и фармацевтическая композиция, содержащая эти соединения
WO2005040345A3 (en) 4-azole substituted imidazole compositions useful as inhibitors or c-met receptor tyrosine kinase
EP1775289A4 (de) Neue imidazolidinderivate
EA200501148A1 (ru) Пиридилоксиметильные и бензизоксазольные азабициклические производные
DE69937045D1 (de) Cyclische amidderivate
EA200200611A1 (ru) Новые тетрагидропиридины, способ их получения и содержащие их фармацевтические композиции
ATE211137T1 (de) Substituierte benzylthienylpiperazine, ihre anwendung als arzneimittel und verfahren für ihre herstellung
EA200401077A1 (ru) 2-оксазоламины и их применение в качестве антагонистов рецептора 5-ht2b
SE8804688L (sv) Substituerade styrenderivat
DK0734384T3 (da) 3-substituerede 1-arylindolforbindelser
ATE386735T1 (de) Substituierte benzoylureidopyridyl-piperidin- und pyrrolidin-carbons urederivate, verfahren zu deren herstellung und deren v erwendung
EA200600551A1 (ru) Соединения пиперазина, способ их получения и фармацевтические композиции, которые их содержат
EP0825180A4 (de) 1-omega-(3,4-dihydro-2-naphtalenyl)alkyl derivate zyklischer amine, verfahren zu ihrer herstellung und medizinische zusammensetzung die diese enthält

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties